Evidence map›Paper›PMID 26935826›Full record

ReviewMedical microbiology and immunology2016

Eradication of measles: remaining challenges.

Heidemarie Holzmann, Hartmut Hengel, Matthias Tenbusch, H W Doerr

Open access · hybridAbstract readReview
In one paragraph

Review in Medical microbiology and immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. The Risk from Reopening International Travel During a Disease X Pandemic: A Case Study of SARS-CoV-2.Risk analysis : an official publication of the Society for Risk Analysis · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Are Measles-Mumps-Rubella (MMR) Antibodies Friends or Foes for Covid-19 Disease?Archivum immunologiae et therapiae experimentalis · 2023
    Article
  10. [Vaccination Gaps of Employees in Institutions of Preschool Childcare before Introduction of the Measles Protection Act].Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) · 2023
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Heidemarie HolzmannDepartment of Virology, Medical University of Vienna, Vienna, Austria. Heidemarie.Holzmann@meduniwien.ac.at.
Hartmut HengelInstitute of Virology, University Medical Center, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
Matthias TenbuschDepartment of Molecular and Medical Virology, Ruhr-University Bochum, Bochum, Germany.
H W DoerrInstitute for Medical Virology, Goethe-University Hospital Frankfurt, Frankfurt/M., Germany.
Medical University of Vienna · ATRuhr University Bochum · DEUniversity Hospital Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measles virus (MeV) is an aerosol-borne and one of the most contagious pathogenic viruses known. Almost every MeV infection becomes clinically manifest and can lead to serious and even fatal complications, especially under conditions of malnutrition in developing countries, where still 115,000 to 160,000 patients die from measles every year. There is no specific antiviral treatment. In addition, MeV infections cause long-lasting memory B and T cell impairment, predisposing people susceptible to opportunistic infections for years. A rare, but fatal long-term consequence of measles is subacute sclerosing panencephalitis. Fifteen years ago (2001), WHO has launched a programme to eliminate measles by a worldwide vaccination strategy. This is promising, because MeV is a human-specific morbillivirus (i.e. without relevant animal reservoir), safe and potent vaccine viruses are sufficiently produced since decades for common application, and millions of vaccine doses have been used globally without any indications of safety and efficacy issues. Though the prevalence of wild-type MeV infection has decreased by >90 % in Europe, measles is still not eliminated and has even re-emerged with recurrent outbreaks in developed countries, in which effective vaccination programmes had been installed for decades. Here, we discuss the crucial factors for a worldwide elimination of MeV: (1) efficacy of current vaccines, (2) the extremely high contagiosity of MeV demanding a >95 % vaccination rate based on two doses to avoid primary vaccine failure as well as the installation of catch-up vaccination programmes to fill immunity gaps and to achieve herd immunity, (3) the implications of sporadic cases of secondary vaccine failure, (4) organisation, acceptance and drawbacks of modern vaccination campaigns, (5) waning public attention to measles, but increasing concerns from vaccine-associated adverse reactions in societies with high socio-economic standards and (6) clinical, epidemiological and virological surveillance by the use of modern laboratory diagnostics and reporting systems. By consequent implementation of carefully designed epidemiologic and prophylactic measures, it should be possible to eradicate MeV globally out of mankind, as the closely related morbillivirus of rinderpest could be successfully eliminated out of the cattle on a global scale.

Indexed as

Disease EradicationEpidemiological MonitoringGlobal HealthHumansImmunization ScheduleMeaslesMeasles VaccineVaccinationMeasles VaccineEliminationEradicationHerd immunityMeaslesSurveillanceVaccination

Identifiers

PMID26935826
PMCPMC4866980
OpenAlexW2290265979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.